Drug Profile


Alternative Names: Omidria; OMS-302; OMS-302-PE; Phenylephrine/ketorolac

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator Omeros Corporation
  • Class Analgesics; Anti-inflammatories; Antihypotensives; Decongestants; Ethanolamines; Eye disorder therapies; Indoles; Mydriatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Miosis; Postoperative pain

Most Recent Events

  • 21 Nov 2016 Efficacy and safety data from a phase III trial in Miosis (In children, In infants, In neonates, Prevention) and Postoperative pain (In children, In infants, In neonates) released by Omeros
  • 29 Jun 2016 Omeros Corporation completes enrolment in its phase III trial for Postoperative pain (In children, In infants, In neonates) and Miosis (Prevention, In children, In infants, In neonates) in USA (Intraocular)
  • 10 May 2016 Omeros and ITROM Trading Drug Store enter into an agreement for the supply and distribution of ketorolac/phenylephrine in the Kingdom of Saudi Arabia, the United Arab Emirates and other countries in the Middle East
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top